IgD multiple myeloma: biology, diagnosis, and treatment

Philip A. Egan, Sheila J. M. O’Connor, W. Ian Deighan, Conal E. McConville, Patrick T. Elder, T. C. M. (Curly) Morris, H. Denis Alexander

Research output: Contribution to journalArticlepeer-review

61 Downloads (Pure)


IgD multiple myeloma is uncommon. Patients generally present at a younger age and have shorter progression free and overall survivals (OSs). Its rarity has inhibited development of a specific risk stratification system or informed best treatment protocols. We present interphase fluorescence in situ hybridization results from a group of 29 cases. These showed evidence of a decreased male to female ratio, decreased OS in patients aged 70 and over, better outcomes in those with kappa light chain restriction, and CD56 positive patients had longer survivals than those lacking CD56. We discuss the biology of IgD multiple myeloma, the need for prospective studies, and challenges for improvements in diagnosis and treatment. We suggest an International Register to accelerate development of best practice guidelines for diagnosis, risk stratification, and treatment.

Original languageEnglish
Pages (from-to)3433-3437
Number of pages5
JournalLeukemia and Lymphoma
Issue number14
Early online date20 Oct 2022
Publication statusPublished online - 20 Oct 2022


  • Cancer Research
  • Oncology
  • Hematology
  • overall survivals
  • IgD multiple myeloma
  • iFISH
  • B cell ontogeny
  • discretionary reflex IFE


Dive into the research topics of 'IgD multiple myeloma: biology, diagnosis, and treatment'. Together they form a unique fingerprint.

Cite this